Abbott India Limited has announced a series of key leadership transitions and board restructuring. The changes include the appointment of new independent and non-executive directors, the resignation of an existing director, and a realignment of senior management personnel. These strategic moves, effective across April and June 2026, aim to ensure continued governance excellence and operational efficiency as the company navigates its next phase of growth.
Board Restructuring
As part of its ongoing governance rotation, the Board has announced that Ms. Anisha Motwani will conclude her second term as an Independent Director at the close of business on April 24, 2026. Concurrently, the Board has appointed Mr. Neeraj Jain as an Additional Director, designated as an Independent Director, for a three-year term effective April 25, 2026. Furthermore, Ms. Alison Davies has resigned from her position as Director effective April 22, 2026.
Strategic Appointments
To further strengthen the board, Mr. James Wenner has been appointed as an Additional (Non-Executive) Director effective April 23, 2026. Both the appointments of Mr. Jain and Mr. Wenner are subject to approval by the company’s members via a postal ballot process. Mr. Jain brings over 30 years of management experience in finance and supply chain, while Mr. Wenner, a current Vice President at Abbott Laboratories, brings deep global financial and audit expertise.
Senior Management Realignment
The company also announced internal changes within its senior management. Mr. Tushar Singh, the current Plant Director for Goa, will be moving to another affiliate of the company effective June 1, 2026, and will cease his role on May 31, 2026. Succeeding him, Mr. Amol Metkar will assume the role of Plant Director – Goa starting June 1, 2026. Mr. Metkar previously led significant manufacturing and operational improvements at the company’s Baddi facility.
Source: BSE
